Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238049789> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4238049789 endingPage "841" @default.
- W4238049789 startingPage "836" @default.
- W4238049789 abstract "Human monoclonal antibodies (HuMAbs) demonstrate great potential for passive immunotherapy against HIV-1. The gp41 transmembrane envelope glycoprotein of HIV has an important role in the pathogenicity of AIDS and importantly displays considerably less hypervariability than the gp120 surface envelope HIV glycoprotein, which makes it particularly a better candidate for the development of passive and active immunotherapies. The general aim of this study was to develop HuMAbs to HIV surface glycoproteins and particularly gp41. Peripheral blood mononuclear cells (PBMCs) were isolated from an HIV-seropositive long-term nondisease progressing patient. B-cells from this individual were then immortalized by Epstein-Barr virus (EBV) transformation, and antibody production was stabilized by fusion of transformed cells with a heteromyeloma. Subsets of the human heterohybridomas so generated were analyzed by ELISA. The hybridoma with the highest binding by immunoassay against gp160 was further analyzed. This hybridoma, designated as clone 37 (C37), was determined to be an IgM Kappa antibody and overlapping peptides of HIV envelope proteins (derived from the MN tissue culture line adapted HIV isolate) were used to map the specific binding domain of this HuMAb. Overlapping peptides designated 2026 (SWSNKSLDDIWNN, AA614–626), and 2027 (DDIWNNMTWMQWEREIDNYT, AA621–640) within the HIV-1 gp41 transmembrane glycoprotein were demonstrated to bind to C37 indicating that the specific binding domain for the antibody was DDIWNN. High affinity binding of C37 by ELISA to recombinant gp41 was demonstrated as well. Few IgM HuMAbs against HIV have been generated and characterized. Theoretically, because of the pentameric binding nature of IgM antibodies as well as their very efficient ability to activate complement, such reagents could have potential as anti-HIV agents." @default.
- W4238049789 created "2022-05-12" @default.
- W4238049789 creator A5036864231 @default.
- W4238049789 creator A5039947785 @default.
- W4238049789 creator A5045380854 @default.
- W4238049789 creator A5047198236 @default.
- W4238049789 creator A5054451714 @default.
- W4238049789 creator A5064956971 @default.
- W4238049789 creator A5090548503 @default.
- W4238049789 date "2004-12-01" @default.
- W4238049789 modified "2023-09-30" @default.
- W4238049789 title "Characterization of a Novel Human Anti-HIV-1 gp41 IgM Monoclonal Antibody Designated Clone 37" @default.
- W4238049789 doi "https://doi.org/10.1089/1044549042729649" @default.
- W4238049789 hasPublicationYear "2004" @default.
- W4238049789 type Work @default.
- W4238049789 citedByCount "0" @default.
- W4238049789 crossrefType "journal-article" @default.
- W4238049789 hasAuthorship W4238049789A5036864231 @default.
- W4238049789 hasAuthorship W4238049789A5039947785 @default.
- W4238049789 hasAuthorship W4238049789A5045380854 @default.
- W4238049789 hasAuthorship W4238049789A5047198236 @default.
- W4238049789 hasAuthorship W4238049789A5054451714 @default.
- W4238049789 hasAuthorship W4238049789A5064956971 @default.
- W4238049789 hasAuthorship W4238049789A5090548503 @default.
- W4238049789 hasConcept C104317684 @default.
- W4238049789 hasConcept C108625454 @default.
- W4238049789 hasConcept C137061746 @default.
- W4238049789 hasConcept C153911025 @default.
- W4238049789 hasConcept C159047783 @default.
- W4238049789 hasConcept C159654299 @default.
- W4238049789 hasConcept C195616568 @default.
- W4238049789 hasConcept C202751555 @default.
- W4238049789 hasConcept C203014093 @default.
- W4238049789 hasConcept C2522874641 @default.
- W4238049789 hasConcept C2776258796 @default.
- W4238049789 hasConcept C40767141 @default.
- W4238049789 hasConcept C542903549 @default.
- W4238049789 hasConcept C55493867 @default.
- W4238049789 hasConcept C81089528 @default.
- W4238049789 hasConcept C86803240 @default.
- W4238049789 hasConcept C97380033 @default.
- W4238049789 hasConceptScore W4238049789C104317684 @default.
- W4238049789 hasConceptScore W4238049789C108625454 @default.
- W4238049789 hasConceptScore W4238049789C137061746 @default.
- W4238049789 hasConceptScore W4238049789C153911025 @default.
- W4238049789 hasConceptScore W4238049789C159047783 @default.
- W4238049789 hasConceptScore W4238049789C159654299 @default.
- W4238049789 hasConceptScore W4238049789C195616568 @default.
- W4238049789 hasConceptScore W4238049789C202751555 @default.
- W4238049789 hasConceptScore W4238049789C203014093 @default.
- W4238049789 hasConceptScore W4238049789C2522874641 @default.
- W4238049789 hasConceptScore W4238049789C2776258796 @default.
- W4238049789 hasConceptScore W4238049789C40767141 @default.
- W4238049789 hasConceptScore W4238049789C542903549 @default.
- W4238049789 hasConceptScore W4238049789C55493867 @default.
- W4238049789 hasConceptScore W4238049789C81089528 @default.
- W4238049789 hasConceptScore W4238049789C86803240 @default.
- W4238049789 hasConceptScore W4238049789C97380033 @default.
- W4238049789 hasIssue "12" @default.
- W4238049789 hasLocation W42380497891 @default.
- W4238049789 hasOpenAccess W4238049789 @default.
- W4238049789 hasPrimaryLocation W42380497891 @default.
- W4238049789 hasRelatedWork W176140375 @default.
- W4238049789 hasRelatedWork W1964097366 @default.
- W4238049789 hasRelatedWork W1971336585 @default.
- W4238049789 hasRelatedWork W1983569464 @default.
- W4238049789 hasRelatedWork W1996225916 @default.
- W4238049789 hasRelatedWork W1996802981 @default.
- W4238049789 hasRelatedWork W2067189024 @default.
- W4238049789 hasRelatedWork W2131805882 @default.
- W4238049789 hasRelatedWork W2151567201 @default.
- W4238049789 hasRelatedWork W2245075643 @default.
- W4238049789 hasVolume "23" @default.
- W4238049789 isParatext "false" @default.
- W4238049789 isRetracted "false" @default.
- W4238049789 workType "article" @default.